Sugi Predict

Sugi Predict / Compounds / SCHEMBL4601165

SCHEMBL4601165

SCHEMBL4601165

C[C@H](c1ccccc1)N1CCC(=O)CC1

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 1/20 0.70
▸ MC4R P32245 1/20 0.61
▸ OPRM1 P35372 4/20 0.51
▸ OPRK1 P41145 3/20 0.51
▸ OPRL1 P41146 3/20 0.51
▸ OPRD1 P41143 2/20 0.51
▸ CHRM2 P08172 5/20 0.51
▸ CHRM1 P11229 5/20 0.51
▸ ALDH1A1 P00352 3/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ HSD11B1 P28845 1/20 0.50
▸ TRPC5 Q9UL62 1/20 0.46
▸ HDAC4 P56524 1/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19613500 1.00 CYP2D6 (0.70) CYP2D6MC4ROPRM1OPRK1OPRL1
SCHEMBL1586528 1.00 CYP2D6 (0.70) CYP2D6MC4ROPRM1OPRK1OPRL1
SCHEMBL8099850 1.00 CYP2D6 (0.70) CYP2D6MC4ROPRM1OPRK1OPRL1
SCHEMBL15463979 0.89 CYP2D6 (0.60) CYP2D6MC4ROPRM1OPRK1OPRL1
SCHEMBL13283877 0.85 HSD11B1 (0.52) CYP2D6MC4ROPRM1CHRM2CHRM1
SCHEMBL27707644 0.84 CYP2D6 (0.50) CYP2D6MC4ROPRM1OPRK1OPRL1
SCHEMBL16226061 0.83 CYP2D6 (1.00) CYP2D6MC4ROPRM1OPRK1OPRL1
SCHEMBL6706135 0.83 CYP2D6 (1.00) CYP2D6MC4ROPRM1OPRK1OPRL1
SCHEMBL7264542 0.83 CYP2D6 (1.00) CYP2D6MC4ROPRM1OPRK1OPRL1
SCHEMBL12685149 0.83 HSD11B1 (0.54) CYP2D6MC4ROPRM1CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12370183-B2 Compositions and methods for treating malaria RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2025-07-29 — — US disclosed
CN-112638898-B Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors 泽农医药公司 2024-04-09 — — CN disclosed
US-20230139910-A1 COMPOSITIONS AND METHODS FOR TREATING MALARIA UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2023-05-04 — — US disclosed
US-20220348577-A1 CXCR4 Receptor Antagonists PROXIMAGEN LLC (US) 2022-11-03 — — US disclosed
US-11299490-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2022-04-12 — — US disclosed
US-10995091-B2 CXCR4 receptor antagonists PROXIMAGEN LLC (US) 2021-05-04 — — US disclosed
US-10995091-B2 CXCR4 receptor antagonists PROXIMAGEN LLC (US) 2021-05-04 — — US disclosed
CN-112638898-A Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors 泽农医药公司 2021-04-09 — — CN disclosed
CN-109526219-B Benzenesulfonamides and their use as therapeutic agents 泽农医药公司 2021-03-12 — — CN disclosed
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-11-12 — — US disclosed
EP-0979819-B1 Process for the production of substituted 3-hydroxypiperidines SPEEDEL PHARMA AG (CH) 2008-04-23 — — EP disclosed
EP-0979824-B1 Process for the preparation of substituted piperidine-epoxides HOFFMANN LA ROCHE (CH) 2004-10-06 — — EP disclosed
EP-0963987-B1 Spiro(piperidine-4,1'-pyrrolo(3,4-c)pyrrole) HOFFMANN LA ROCHE (CH) 2002-08-28 — — EP disclosed
US-6274735-B1 RENIN INHIBITORS HOFFMANN-LA ROCHE INC. 2001-08-14 — — US disclosed
US-6268499-B1 USEFUL AS RENIN INHIBITORS HOFFMAN-LA ROCHE INC. 2001-07-31 — — US disclosed
WO-2000063173-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED PIPERIDINES F. HOFFMANN-LA ROCHE AG (CH) 2000-10-26 — — WO disclosed
US-6075034-A Spiro[piperidine-4,1'-pyrrolo [3,4-C] pyrrole]derivatives HOFFMANN-LA ROCHE INC. (US) 2000-06-13 — — US disclosed
EP-0979824-A1 Process for the preparation of substituted piperidine-epoxides F. HOFFMANN-LA ROCHE AG (CH) 2000-02-16 — — EP disclosed
EP-0979819-A1 Process for the production of substituted 3-hydroxypiperidines F. HOFFMANN-LA ROCHE AG (CH) 2000-02-16 — — EP disclosed
EP-0963987-A2 Spiro(piperidine-4,1'-pyrrolo(3,4-c)pyrrole) F. HOFFMANN-LA ROCHE AG (CH) 1999-12-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348577-A1 CXCR4 Receptor Antagonists CXCR4, CXCR1, CXCR2 CYP2D6 1788/4885MC4R 295/4885OPRM1 83/4885
US-12370183-B2 Compositions and methods for treating malaria G6PD, QDPR, FASN CYP2D6 233/4885MC4R 1523/4885OPRM1 4026/4885
US-11299490-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B CYP2D6 321/4885MC4R 3389/4885OPRM1 1712/4885
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B CYP2D6 321/4885MC4R 3389/4885OPRM1 1712/4885
US-20230139910-A1 COMPOSITIONS AND METHODS FOR TREATING MALARIA G6PD, QDPR, FASN CYP2D6 233/4885MC4R 1523/4885OPRM1 4026/4885
US-10995091-B2 CXCR4 receptor antagonists CXCR4, CXCR1, CXCR2 CYP2D6 1788/4885MC4R 295/4885OPRM1 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.